Sor102 Now

Recent Phase 1b clinical data, published in journals like The Lancet Gastroenterology & Hepatology , highlight three critical advantages of SOR102:

One patient reported a mild TEAE of catheter site pain and another patient reported a mild TEAE of headache in the placebo group. ... ScienceDirect.com Study Details | NCT06080048 - Clinical Trials SOR102-101 is a Phase 1, 3-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, an... Clinical Trials.gov Reaching the therapeutic ceiling in IBD: Can Advanced Combination ... SOR102 was well tolerated across all doses, with no systemic exposure of the drug or its monomers, supporting its gut-targeted act... ScienceDirect.com Publications - Sorriso Pharmaceuticals The Lancet Gastroenterology & Hepatology. | 2025. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and i... Sorriso Pharmaceuticals Safety and pharmacokinetics of SOR102, an oral bispecific ... Dec 22, 2025 — sor102

Recent studies suggest that blocking both TNF and IL-23 is more effective than blocking either one alone. SOR102 does this within a single molecule. Future Outlook Recent Phase 1b clinical data, published in journals

Once you let me know, I’ll draft a complete feature description, including purpose, functionality, user stories, and example use cases. Clinical Trials

If "sor102" is a course or educational topic, here's a basic outline: